aminopropionitrile has been researched along with Fibrosis in 16 studies
Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since, LOX enzymes need copper (Cu) for their proper catalytic activity; the present study investigated the efficacy of a copper chelator, disulfiram (DSF) in renal fibrosis." | 8.12 | Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. ( Godugu, C; Kaki, VR; Saifi, MA; Shaikh, AS, 2022) |
| " β-Aminopropionitrile (BAPN), an inhibitor of LOX activity, significantly attenuated the increase in body weight and cardiac hypertrophy observed in HFD rats." | 7.83 | The lysyl oxidase inhibitor (β-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats. ( Bartolomé, MV; Cachofeiro, V; Galán, M; Islas, F; Jurado-López, R; López-Andrés, N; Luaces, M; Martínez-González, J; Martínez-Martínez, E; Miana, M; Rodríguez, C, 2016) |
| "Fibrosis/contracture is associated with the abnormal persistence of myofibroblasts, which over-produce and contract collagen matrices." | 5.56 | Sulfasalazine Resolves Joint Stiffness in a Rabbit Model of Arthrofibrosis. ( Atluri, K; Brouillette, MJ; Fowler, TP; Fredericks, D; Khorsand, B; Martin, JA; Petersen, E; Salem, AK; Sander, E; Seol, D; Smith, S, 2020) |
| " Since, LOX enzymes need copper (Cu) for their proper catalytic activity; the present study investigated the efficacy of a copper chelator, disulfiram (DSF) in renal fibrosis." | 4.12 | Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. ( Godugu, C; Kaki, VR; Saifi, MA; Shaikh, AS, 2022) |
| " β-Aminopropionitrile (BAPN), an inhibitor of LOX activity, significantly attenuated the increase in body weight and cardiac hypertrophy observed in HFD rats." | 3.83 | The lysyl oxidase inhibitor (β-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats. ( Bartolomé, MV; Cachofeiro, V; Galán, M; Islas, F; Jurado-López, R; López-Andrés, N; Luaces, M; Martínez-González, J; Martínez-Martínez, E; Miana, M; Rodríguez, C, 2016) |
| "While fibrosis is primarily characterized by an accumulation of extracellular matrix (ECM) components, there are changes in ECM architecture during fibrosis that relate more closely to functional muscle stiffness." | 1.72 | Collagen cross-links scale with passive stiffness in dystrophic mouse muscles, but are not altered with administration of a lysyl oxidase inhibitor. ( Brashear, SE; Christiansen, BA; Hu, LY; Jbeily, EH; Smith, LR; Wohlgemuth, RP, 2022) |
| "Fibrosis/contracture is associated with the abnormal persistence of myofibroblasts, which over-produce and contract collagen matrices." | 1.56 | Sulfasalazine Resolves Joint Stiffness in a Rabbit Model of Arthrofibrosis. ( Atluri, K; Brouillette, MJ; Fowler, TP; Fredericks, D; Khorsand, B; Martin, JA; Petersen, E; Salem, AK; Sander, E; Seol, D; Smith, S, 2020) |
| "Renal fibrosis is a common pathological manifestation of almost all forms of kidney disease irrespective of the etiological cause." | 1.56 | Inhibition of lysyl oxidase ameliorates renal injury by inhibiting CD44-mediated pericyte detachment and loss of peritubular capillaries. ( Godugu, C; Saifi, MA, 2020) |
| "Cardiac fibrosis is a hallmark of heart failure for which there is no effective pharmacological therapy." | 1.51 | Inhibition of Rho-associated kinases suppresses cardiac myofibroblast function in engineered connective and heart muscle tissues. ( Hartmann, S; Lutz, S; Ridley, A; Santos, GL; Zimmermann, WH, 2019) |
| " We studied the functional contribution of lysyl oxidase (LOX) to collagen stabilization and hepatic fibrosis progression/reversalin vivousing chronic administration of irreversible LOX inhibitor β-aminopropionitrile (BAPN, or vehicle as control) in C57Bl/6J mice with carbon tetrachloride (CCl4)-induced fibrosis." | 1.43 | Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. ( Greenstein, A; Ikenaga, N; Liu, SB; Peng, ZW; Popov, Y; Schuppan, D; Smith, V; Sverdlov, DY, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rowbottom, MW | 1 |
| Bain, G | 1 |
| Calderon, I | 1 |
| Lasof, T | 1 |
| Lonergan, D | 1 |
| Lai, A | 1 |
| Huang, F | 1 |
| Darlington, J | 1 |
| Prodanovich, P | 1 |
| Santini, AM | 1 |
| King, CD | 1 |
| Goulet, L | 1 |
| Shannon, KE | 1 |
| Ma, GL | 1 |
| Nguyen, K | 1 |
| MacKenna, DA | 1 |
| Evans, JF | 1 |
| Hutchinson, JH | 1 |
| Saifi, MA | 2 |
| Shaikh, AS | 1 |
| Kaki, VR | 1 |
| Godugu, C | 2 |
| Brashear, SE | 1 |
| Wohlgemuth, RP | 1 |
| Hu, LY | 1 |
| Jbeily, EH | 1 |
| Christiansen, BA | 1 |
| Smith, LR | 1 |
| Atluri, K | 1 |
| Brouillette, MJ | 1 |
| Seol, D | 1 |
| Khorsand, B | 1 |
| Sander, E | 1 |
| Salem, AK | 1 |
| Fredericks, D | 1 |
| Petersen, E | 1 |
| Smith, S | 1 |
| Fowler, TP | 1 |
| Martin, JA | 1 |
| Gao, L | 1 |
| Wu, C | 1 |
| Fu, F | 1 |
| You, X | 1 |
| Ma, X | 1 |
| Qin, F | 1 |
| Li, T | 1 |
| Wang, R | 1 |
| Yuan, J | 1 |
| Santos, GL | 1 |
| Hartmann, S | 1 |
| Zimmermann, WH | 1 |
| Ridley, A | 1 |
| Lutz, S | 1 |
| Rosin, NL | 1 |
| Sopel, MJ | 1 |
| Falkenham, A | 1 |
| Lee, TD | 1 |
| Légaré, JF | 1 |
| Miana, M | 2 |
| Galán, M | 2 |
| Martínez-Martínez, E | 2 |
| Varona, S | 1 |
| Jurado-López, R | 2 |
| Bausa-Miranda, B | 1 |
| Antequera, A | 1 |
| Luaces, M | 2 |
| Martínez-González, J | 2 |
| Rodríguez, C | 2 |
| Cachofeiro, V | 2 |
| Liu, SB | 1 |
| Ikenaga, N | 1 |
| Peng, ZW | 1 |
| Sverdlov, DY | 1 |
| Greenstein, A | 1 |
| Smith, V | 1 |
| Schuppan, D | 1 |
| Popov, Y | 1 |
| Bartolomé, MV | 1 |
| Islas, F | 1 |
| López-Andrés, N | 1 |
| Hassan, SI | 1 |
| Ali, I | 1 |
| Nessim, NG | 1 |
| Amer, NM | 1 |
| Abd el Kader el Khafif, M | 1 |
| Ashour, A | 1 |
| el Mohandes, M | 1 |
| Giampuzzi, M | 1 |
| Botti, G | 1 |
| Di Duca, M | 1 |
| Arata, L | 1 |
| Ghiggeri, G | 1 |
| Gusmano, R | 1 |
| Ravazzolo, R | 1 |
| Di Donato, A | 1 |
| Kagan, HM | 2 |
| Hefetz, L | 1 |
| Naveh, N | 1 |
| Tang, SS | 1 |
| Chichester, CO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram[NCT03212599] | 17 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19[NCT04594343] | Phase 2 | 140 participants (Actual) | Interventional | 2020-11-20 | Completed | ||
| A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma[NCT04521335] | Phase 1 | 2 participants (Actual) | Interventional | 2021-05-21 | Terminated (stopped due to Closed at PI's Request) | ||
| DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
| Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder[NCT02735577] | Phase 4 | 7 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | units on a scale (Median) |
|---|---|
| Cohort 1: Disulfiram | -2.60 |
| Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | copies/mL (Mean) |
|---|---|
| Cohort 1: Disulfiram 1000 mg | -20.89 |
| Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | fold change (Median) | |
|---|---|---|
| Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
| Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
| Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE Grade 3 or Higher | AE Grade 1 or 2 | |
| Cohort 1: Disulfiram 1000 mg | 0 | 4 |
| Cohort 1: Placebo | 1 | 1 |
Number of drinking days (NCT02735577)
Timeframe: 42 days
| Intervention | days (Mean) |
|---|---|
| Disulfiram | 0 |
2 reviews available for aminopropionitrile and Fibrosis
| Article | Year |
|---|---|
Intra- and extracellular enzymes of collagen biosynthesis as biological and chemical targets in the control of fibrosis.
Topics: Aminopropionitrile; Animals; Benzylamines; Cells, Cultured; Collagen; Enzyme Inhibitors; Esters; Eth | 2000 |
[Use of drugs inhibiting fibrosis after trabeculectomy].
Topics: Adrenal Cortex Hormones; Aminopropionitrile; Fibrosis; Fluorouracil; Humans; Mitomycin; Postoperativ | 1992 |
14 other studies available for aminopropionitrile and Fibrosis
| Article | Year |
|---|---|
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
Topics: Administration, Oral; Amino Acid Oxidoreductases; Animals; Disease Models, Animal; Enzyme Inhibitors | 2017 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Collagen cross-links scale with passive stiffness in dystrophic mouse muscles, but are not altered with administration of a lysyl oxidase inhibitor.
Topics: Aminopropionitrile; Animals; Collagen; Disease Models, Animal; Fibrosis; Mice; Mice, Inbred mdx; Mus | 2022 |
Sulfasalazine Resolves Joint Stiffness in a Rabbit Model of Arthrofibrosis.
Topics: Aminopropionitrile; Animals; Collagen; Contracture; Disease Models, Animal; Fibrosis; Hydroxyproline | 2020 |
Inhibition of lysyl oxidase ameliorates renal injury by inhibiting CD44-mediated pericyte detachment and loss of peritubular capillaries.
Topics: Aminopropionitrile; Animals; Capillaries; Catalysis; Collagen; Epithelial-Mesenchymal Transition; Fi | 2020 |
Effect of lysyl oxidase (LOX) on corpus cavernous fibrosis caused by ischaemic priapism.
Topics: Aminopropionitrile; Animals; Cell Proliferation; Collagen Type I; Collagen Type III; Disease Models, | 2018 |
Inhibition of Rho-associated kinases suppresses cardiac myofibroblast function in engineered connective and heart muscle tissues.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Aminopropionitrile; Animals; Cell Differentia | 2019 |
Disruption of collagen homeostasis can reverse established age-related myocardial fibrosis.
Topics: Age Factors; Aminopropionitrile; Animals; Collagen; Fibrosis; Heart; Heart Diseases; Male; Mice; Myo | 2015 |
The lysyl oxidase inhibitor β-aminopropionitrile reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adiposity; Aminopropionitrile; Animals; Cell Size; Collagen; | 2015 |
Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice.
Topics: Aminopropionitrile; Animals; Carbon Tetrachloride; Collagen; Collagen Type I; Collagen Type I, alpha | 2016 |
The lysyl oxidase inhibitor (β-aminopropionitrile) reduces leptin profibrotic effects and ameliorates cardiovascular remodeling in diet-induced obesity in rats.
Topics: Aminopropionitrile; Animals; Aorta; Blood Pressure; Body Weight; Diet, High-Fat; Extracellular Matri | 2016 |
Treatment of acute schistosomiasis mansoni with praziquantel and an antifibrotic agent in mice. Maintenance of resistance to infection.
Topics: Acute Disease; Aminopropionitrile; Animals; Antiplatyhelmintic Agents; Drug Resistance; Fibrosis; Gr | 2003 |
Lysyl oxidase activates the transcription activity of human collagene III promoter. Possible involvement of Ku antigen.
Topics: Aminopropionitrile; Animals; Antigens, Nuclear; Base Sequence; Collagen; COS Cells; DNA Helicases; D | 2000 |
Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors.
Topics: Amine Oxidase (Copper-Containing); Amino Acid Oxidoreductases; Aminopropionitrile; Animals; Binding | 1989 |